Login / Signup

Letter: interpretation of the BESST trial in the context of baseline antidepressant and neuromodulator use.

Brent HiramotoWalter Wai-Yip Chan
Published in: Alimentary pharmacology & therapeutics (2023)
Keyphrases
  • major depressive disorder
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • open label
  • bipolar disorder